Prothena Corp. (Nasdaq: PRTA) is discontinuing the development of NEOD001 to treat AL amyloidosis after disappointing Phase 2b PRONTO study results. Shares of the biotechnology firm plummeted $25.34 to close at $11.50.
Prothena discontinues NEOD001 development
April 23, 2018 at 17:11 PM EDT
